Enveric Biosciences Participating in BIO-Europe Spring®
Enveric Biosciences (NASDAQ: ENVB) announced its participation in BIO-Europe Spring®, taking place in Milan, Italy, March 17-19, 2025. The biotechnology company, focused on developing novel neuroplastogenic small-molecule therapeutics for anxiety, depression, and addiction disorders, will conduct one-on-one meetings with investors and potential partners during the event.
The company plans to showcase its business strategy, clinical development progress, recent achievements, and upcoming milestones. CEO Joseph Tucker highlighted their strategic approach to developing neuroplastogenic molecules, particularly EB-003, emphasizing their focus on eliminating or reducing hallucinatory effects common to N,N-Dimethyltryptamine (DMT), mescaline and related analogs as key to commercial success.
Enveric Biosciences (NASDAQ: ENVB) ha annunciato la sua partecipazione a BIO-Europe Spring®, che si terrà a Milano, Italia, dal 17 al 19 marzo 2025. L'azienda biotecnologica, focalizzata sullo sviluppo di nuovi terapie neuroplastogeniche a base di piccole molecole per disturbi d'ansia, depressione e dipendenza, condurrà incontri individuali con investitori e potenziali partner durante l'evento.
L'azienda prevede di presentare la propria strategia aziendale, i progressi nello sviluppo clinico, i successi recenti e i traguardi futuri. Il CEO Joseph Tucker ha evidenziato il loro approccio strategico nello sviluppo di molecole neuroplastogeniche, in particolare EB-003, sottolineando l'importanza di eliminare o ridurre gli effetti allucinogeni comuni a N,N-Dimetiltriptamina (DMT), mescalina e analoghi correlati come chiave per il successo commerciale.
Enveric Biosciences (NASDAQ: ENVB) anunció su participación en BIO-Europe Spring®, que se llevará a cabo en Milán, Italia, del 17 al 19 de marzo de 2025. La empresa biotecnológica, enfocada en desarrollar nuevas terapias neuroplastogénicas de pequeñas moléculas para trastornos de ansiedad, depresión y adicción, llevará a cabo reuniones uno a uno con inversores y posibles socios durante el evento.
La compañía planea presentar su estrategia comercial, el progreso en el desarrollo clínico, los logros recientes y los hitos futuros. El CEO Joseph Tucker destacó su enfoque estratégico para desarrollar moléculas neuroplastogénicas, en particular EB-003, enfatizando su enfoque en eliminar o reducir los efectos alucinógenos comunes a la N,N-Dimetiltriptamina (DMT), mescalina y análogos relacionados como clave para el éxito comercial.
Enveric Biosciences (NASDAQ: ENVB)는 2025년 3월 17일부터 19일까지 이탈리아 밀라노에서 열리는 BIO-Europe Spring®에 참여한다고 발표했습니다. 불안, 우울증 및 중독 장애를 위한 새로운 신경가소성 소분자 치료제를 개발하는 데 주력하는 생명공학 회사는 행사 동안 투자자 및 잠재적 파트너와의 일대일 회의를 진행할 예정입니다.
회사는 비즈니스 전략, 임상 개발 진행 상황, 최근 성과 및 향후 이정표를 선보일 계획입니다. CEO 조셉 터커는 신경가소성 분자 개발에 대한 전략적 접근 방식을 강조하며, 특히 EB-003에 대해 N,N-디메틸트립타민(DMT), 메스칼린 및 관련 유사체에 일반적인 환각 효과를 제거하거나 감소시키는 데 중점을 두는 것이 상업적 성공의 열쇠라고 강조했습니다.
Enveric Biosciences (NASDAQ: ENVB) a annoncé sa participation à BIO-Europe Spring®, qui se tiendra à Milan, en Italie, du 17 au 19 mars 2025. L'entreprise de biotechnologie, axée sur le développement de nouvelles thérapies neuroplastogènes à base de petites molécules pour les troubles de l'anxiété, de la dépression et de la dépendance, organisera des réunions individuelles avec des investisseurs et des partenaires potentiels pendant l'événement.
L'entreprise prévoit de présenter sa stratégie commerciale, ses avancées en développement clinique, ses réalisations récentes et ses prochaines étapes. Le PDG Joseph Tucker a souligné leur approche stratégique pour développer des molécules neuroplastogènes, en particulier EB-003, en mettant l'accent sur l'importance d'éliminer ou de réduire les effets hallucinogènes courants de la N,N-Diméthyltryptamine (DMT), de la mescaline et des analogues connexes comme clé du succès commercial.
Enveric Biosciences (NASDAQ: ENVB) gab die Teilnahme an der BIO-Europe Spring® bekannt, die vom 17. bis 19. März 2025 in Mailand, Italien, stattfindet. Das biotechnologische Unternehmen, das sich auf die Entwicklung neuartiger neuroplastogener Kleinstmolekültherapeutika für Angstzustände, Depressionen und Suchtstörungen konzentriert, wird während der Veranstaltung Einzelgespräche mit Investoren und potenziellen Partnern führen.
Das Unternehmen plant, seine Geschäftsstrategie, den Fortschritt in der klinischen Entwicklung, kürzliche Erfolge und bevorstehende Meilensteine zu präsentieren. CEO Joseph Tucker hob ihren strategischen Ansatz zur Entwicklung neuroplastogener Moleküle hervor, insbesondere EB-003, und betonte, dass die Beseitigung oder Reduzierung der häufigen halluzinogenen Effekte von N,N-Dimethyltryptamin (DMT), Mescalin und verwandten Analoga der Schlüssel zum kommerziellen Erfolg sei.
- Strategic focus on developing non-hallucinogenic versions of psychedelic compounds
- Active engagement with pharmaceutical industry leaders and potential partners
- None.
During the Spring partnering event, members of Enveric’s management team are conducting one-on-one meetings with registered investors and potential partners, showcasing the company’s business and clinical development strategy, recent corporate achievements, and anticipated milestones.
“We anticipate a highly productive meeting at BIO-Europe Spring as we continue to garner interest in our strategic approach to developing neuroplastogenic molecules, led by EB-003, for the treatment of underserved mental health conditions. Our ongoing discussions with leaders in the pharmaceutical industry clearly indicate that eliminating or substantially reducing the hallucinatory effect common to N,N-Dimethyltryptamine (DMT), mescaline and related analogs will be key to commercial success,” said Joseph Tucker, Ph.D., Director and Chief Executive Officer of Enveric.
About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. Leveraging its unique discovery and development platform, the Psybrary™, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, Enveric seeks to develop a robust intellectual property portfolio of novel drug candidates. Enveric’s lead molecule, EB-003, is a potential first-in-class neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. Enveric is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing all other novel, patented Psybrary™ drug candidates to third-party licensees advancing non-competitive market strategies for patient care. Enveric is headquartered in
Forward-Looking Statements
This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as "plans," "expects" or "does not expect," "proposes," "budgets," "explores," "schedules," "seeks," "estimates," "forecasts," "intends," "anticipates" or "does not anticipate," or "believes," or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND filing to the
A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the Securities and Exchange Commission, including Enveric’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250317853926/en/
Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
dirish@tiberend.com
Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
(646) 577-8520
cmcdonald@tiberend.com
Source: Enveric Biosciences, Inc.
FAQ
What is the main focus of Enveric Biosciences' (ENVB) drug development program?
When and where is Enveric Biosciences (ENVB) participating in BIO-Europe Spring?
What is Enveric Biosciences' (ENVB) approach to developing psychedelic compounds?
What activities will Enveric Biosciences (ENVB) conduct at BIO-Europe Spring 2025?
